Though tumor heterogeneity remains a major cause of the prognostic and therapeutic difficulty in the management of advanced stages of cancer [35], clonal transcriptomic biomarkers such as UBQLN4 upregulation can be very useful in precision oncology treatment decisions. Here, UBQLN4 is linked to neoplasm.